487 related articles for article (PubMed ID: 16699068)
21. Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo.
Fujii T; Ishikawa M; Kubo A; Tanaka Y
Bone; 2015 Dec; 81():427-434. PubMed ID: 26297834
[TBL] [Abstract][Full Text] [Related]
22. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
23. The effects of hyaluronan on bone resorption and bone mineral density in a rat model of estrogen deficiency-induced osteopenia.
Stancíková M; Svík K; Istok R; Rovenský J; Velebný V
Int J Tissue React; 2004; 26(1-2):9-16. PubMed ID: 15573687
[TBL] [Abstract][Full Text] [Related]
24. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
25. Antiosteoporotic activity of OST-6(Osteocare), a herbomineral preparation in calcium deficient ovariectomized rats.
Reddy NP; Lakshmana M; Udupa UV
Phytother Res; 2004 Jan; 18(1):25-9. PubMed ID: 14750196
[TBL] [Abstract][Full Text] [Related]
26. A cytochemical assay for osteoclast cathepsin K activity.
Dodds RA
Cell Biochem Funct; 2003 Sep; 21(3):231-4. PubMed ID: 12910475
[TBL] [Abstract][Full Text] [Related]
27. The biphenyl-carboxylate derivative ABD328 is a novel orally active antiresorptive agent.
Idris AI; Coste E; Greig IR; Ralston SH; van't Hof RJ
Calcif Tissue Int; 2010 Dec; 87(6):525-32. PubMed ID: 20852852
[TBL] [Abstract][Full Text] [Related]
28. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
Dodds RA; James IE; Rieman D; Ahern R; Hwang SM; Connor JR; Thompson SD; Veber DF; Drake FH; Holmes S; Lark MW; Gowen M
J Bone Miner Res; 2001 Mar; 16(3):478-86. PubMed ID: 11277265
[TBL] [Abstract][Full Text] [Related]
29. Effects of wortmannin analogs on bone in vitro and in vivo.
Sato M; Bryant HU; Dodge JA; Davis H; Matter WF; Vlahos CJ
J Pharmacol Exp Ther; 1996 Apr; 277(1):543-50. PubMed ID: 8613966
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.
Morko J; Kiviranta R; Mulari MT; Ivaska KK; Väänänen HK; Vuorio E; Laitala-Leinonen T
Bone; 2009 Apr; 44(4):717-28. PubMed ID: 19118660
[TBL] [Abstract][Full Text] [Related]
31. Cathepsin K: a therapeutic target for bone diseases.
Zhao Q; Jia Y; Xiao Y
Biochem Biophys Res Commun; 2009 Mar; 380(4):721-3. PubMed ID: 19338743
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents.
James IE; Lark MW; Zembryki D; Lee-Rykaczewski EV; Hwang SM; Tomaszek TA; Belfiore P; Gowen M
J Bone Miner Res; 1999 Sep; 14(9):1562-9. PubMed ID: 10469285
[TBL] [Abstract][Full Text] [Related]
33. Triterpenoids from Cimicifugae rhizoma, a novel class of inhibitors on bone resorption and ovariectomy-induced bone loss.
Li JX; Liu J; He CC; Yu ZY; Du Y; Kadota S; Seto H
Maturitas; 2007 Sep; 58(1):59-69. PubMed ID: 17658706
[TBL] [Abstract][Full Text] [Related]
34. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model.
Coelingh Bennink HJ; Heegaard AM; Visser M; Holinka CF; Christiansen C
Climacteric; 2008; 11 Suppl 1():2-14. PubMed ID: 18464016
[TBL] [Abstract][Full Text] [Related]
35. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
Duplat D; Gallet M; Berland S; Marie A; Dubost L; Rousseau M; Kamel S; Milet C; Brazier M; Lopez E; Bédouet L
Biomaterials; 2007 Nov; 28(32):4769-78. PubMed ID: 17686515
[TBL] [Abstract][Full Text] [Related]
36. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Niikura K; Takeshita N; Takano M
J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
[TBL] [Abstract][Full Text] [Related]
37. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Yasuda Y; Kaleta J; Brömme D
Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
39. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
40. Regulation and enzymatic basis of bone resorption by human osteoclasts.
Fuller K; Kirstein B; Chambers TJ
Clin Sci (Lond); 2007 Jun; 112(11):567-75. PubMed ID: 17241109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
